Anu Osinusi
Gilead Sciences (United States)(US)
Publications by Year
Research Areas
Hepatitis C virus research, Hepatitis B Virus Studies, Liver Disease Diagnosis and Treatment, COVID-19 Clinical Research Studies, HIV/AIDS drug development and treatment
Most-Cited Works
- → Remdesivir for the Treatment of Covid-19 — Final Report(2020)7,674 cited
- → Compassionate Use of Remdesivir for Patients with Severe Covid-19(2020)2,902 cited
- → Remdesivir for 5 or 10 Days in Patients with Severe Covid-19(2020)1,431 cited
- → Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19(2020)1,265 cited
- → Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients(2021)1,256 cited
- → Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection(2015)1,110 cited
- → Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection(2015)845 cited
- → Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis(2015)799 cited
- → Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects(2020)262 cited
- → Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection(2015)203 cited